Literature DB >> 10366583

Latent Varicella-zoster virus in human dorsal root ganglia.

P G Kennedy1, E Grinfeld, J W Gow.   

Abstract

To understand further the molecular events underlying the process of Varicella-zoster virus (VZV) latency in human ganglionic tissues, in situ hybridisation (ISH) for VZV RNA and DNA, and PCR in situ amplification for VZV DNA were used in human dorsal root ganglia from 12 individuals (3 normal and 9 who had died with AIDS). The results showed that (a) two separate regions of the VZV genome, represented by genes 4 and 40, were detected in neurons in two normal and three AIDS ganglia, (b) evidence of transcription of VZV genes 4, 21, 29, and 63 was found in normal and AIDS cases, and (c) VZV DNA and RNA for the same gene (gene 29) was detected in neurons in serial tissue sections in three cases. Thus more than one region of the VZV genome is present in neurons during VZV ganglionic latency, and the presence of both a VZV gene and its corresponding RNA transcript can be shown to occur in the same localised region of DRG tissue. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10366583     DOI: 10.1006/viro.1999.9745

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  43 in total

1.  Differentiated neuroblastoma cells provide a highly efficient model for studies of productive varicella-zoster virus infection of neuronal cells.

Authors:  Jenna Christensen; Megan Steain; Barry Slobedman; Allison Abendroth
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

2.  Varicella-zoster virus gene expression in latently infected and explanted human ganglia.

Authors:  P G Kennedy; E Grinfeld; J E Bell
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

3.  Neutralizing anti-gH antibody of Varicella-zoster virus modulates distribution of gH and induces gene regulation, mimicking latency.

Authors:  Kimiyasu Shiraki; Tohru Daikoku; Masaya Takemoto; Yoshihiro Yoshida; Kazuhiro Suzuki; Yasushi Akahori; Toshiomi Okuno; Yoshikazu Kurosawa; Yoshizo Asano
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

4.  Varicella-Zoster Virus Downregulates Programmed Death Ligand 1 and Major Histocompatibility Complex Class I in Human Brain Vascular Adventitial Fibroblasts, Perineurial Cells, and Lung Fibroblasts.

Authors:  Dallas Jones; Anna Blackmon; C Preston Neff; Brent E Palmer; Don Gilden; Hussain Badani; Maria A Nagel
Journal:  J Virol       Date:  2016-11-14       Impact factor: 5.103

Review 5.  Herpes zoster and the search for an effective vaccine.

Authors:  N Arnold; I Messaoudi
Journal:  Clin Exp Immunol       Date:  2016-07-25       Impact factor: 4.330

6.  Herpes viruses hedge their bets.

Authors:  Michael P H Stumpf; Zoe Laidlaw; Vincent A A Jansen
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-30       Impact factor: 11.205

7.  Varicella-zoster virus open reading frame 2 encodes a membrane phosphoprotein that is dispensable for viral replication and for establishment of latency.

Authors:  Hitoshi Sato; Lesley Pesnicak; Jeffrey I Cohen
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

8.  Varicella-zoster virus ORF47 protein kinase, which is required for replication in human T cells, and ORF66 protein kinase, which is expressed during latency, are dispensable for establishment of latency.

Authors:  Hitoshi Sato; Lesley Pesnicak; Jeffrey I Cohen
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

9.  Array analysis of viral gene transcription during lytic infection of cells in tissue culture with Varicella-Zoster virus.

Authors:  Randall J Cohrs; Michael P Hurley; Donald H Gilden
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

10.  Downregulation of varicella-zoster virus (VZV) immediate-early ORF62 transcription by VZV ORF63 correlates with virus replication in vitro and with latency.

Authors:  Susan E Hoover; Randall J Cohrs; Zoila G Rangel; Donald H Gilden; Peter Munson; Jeffrey I Cohen
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.